Two years after Neil Armstrong walked on the Moon, US president Richard Nixon declared a new frontier in American scientific ...

Early research shows a one-time gene therapy has potential for addressing both the liver and lung disease that patients with ...

Adding immunotherapy to new KRAS inhibitors boosted responses in preclinical models, setting the stage for future trials of the combination strategy. The study was published in Cancer Discovery by ...

In 2025, Cellectis will continue to focus its efforts and expenses on advancing its core clinical trials BALLI-01 and NATHALI ...

Momentum Builds Across Programs with Key Data Milestones Expected in 2025Cemacabtagene Ansegedleucel (Cema-Cel): First-Line ...

Three-program alliance with Synaffix reflects SOTIO’s commitment to further broaden and advance innovative ADC pipeline ...

“The KickStart Grant Awards help de-risk these technologies by establishing a collaboration agreement between the startup ...

Biosciences announced the presentation of preclinical data investigating the potential of co-administration of deoxyribonuclease ...

Antibody treatment which activates the patient's own immune system against cancer, known as immunotherapy, is increasingly ...

Our Bureau, Mumbai Thursday, March 13, 2025, 14:15 Hrs [IST] ...

Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...

Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors ...